COM503

COM503 binds to purified human IL18BP with high affinity (K_d = 0.291 pM), which is higher than the affinity between endogenous human IL18 and IL18BP (K_d = 0.441 pM)^[1].
COM503 (1.25-10 μg/mL; 1 h (complex incubation at 37°C); RT or 37°C (assay incubation steps)) displaces IL18 from preformed recombinant human IL18:IL18BP complexes in a dose-dependent manner in vitro, with an EC₅₀ of 14 nM^[1].
COM503 (24 h) restores the activation of human melanoma CD8⁺ tumor-infiltrating lymphocytes (TILs) co-cultured with MEL624 cells and mediated by IL18, and increases the secretion levels of IFN-γ and TNF-α as well as the expression of CD137 in CD8⁺ TILs^[1].
COM503 (24 h) restores IL18-mediated activation of isolated human NK cells blocked by preformed IL18:IL18BP complexes, and increases IFN-γ secretion levels^[1].
COM503 (10 μg/mL; 24 h) restores IL18-mediated activation of CMV-reactive CD8⁺ T cells co-cultured with PD-L1-overexpressing MEL624 cells^[1].
COM503 (24 h) restores IL18-mediated activation of human peripheral blood mononuclear cells (PBMCs) by blocking endogenously secreted IL18BP, and increases IFN-γ secretion levels with a mean EC₅₀ of 1.6 nM^[1].
COM503 (20 μg/mL; 24 h) enhances IFN-γ secretion by human melanoma CD8⁺ tumor-infiltrating lymphocytes (TILs) co-cultured with MEL624 cells through blocking endogenously secreted IL18BP at physiologically relevant IL18 concentrations^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.